arrow
S

Solange Peters

university hospital lausanne chuv
H指数:112
被引数:7.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-reported outcomes from the phase 3 IMforte study of first-line maintenance treatment with lurbinectedin + atezolizumab versus atezolizumab in patients with extensive-stage small cell lung cancer

IMforte III期研究中, lurbinectedin联合atezolizumab作为广泛期小细胞肺癌患者一线维持治疗的疗效与atezolizumab对比的患者报告结局

2026-11-180
PRE
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

抗体药物偶联物在特定实体瘤中的应用:基于ETOP IBCSG Partners基金会第三次研讨会成果的立场声明更新

2026-07-010
OAAI
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective

肺癌中抗体药物偶联物的生物标志物:病理学家的视角

2026-06-010
PRE
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

纳武利尤单抗联合放化疗后序贯纳武利尤单抗联合或不联合伊匹木单抗治疗未经治疗的局部晚期Ⅲ期非小细胞肺癌:一项随机Ⅲ期试验

2026-05-130
OAAI
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1

度瓦尼单抗联合齐木利单抗作为PD-L1高表达、晚期非小细胞肺癌患者的一线治疗:来自随机II期ARC-10研究的结果,第一部分

2026-02-110
OAAI
The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial

参与线上正念基础癌症康复(e-MBCR)计划后,乳腺癌或妇科癌症女性的体验:一项试点混合方法随机对照试验的次要结局分析

2025-11-210
OAAI
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

性别特异性的疗效和安全性结局:在接受新辅助治疗的可切除III期非小细胞肺癌(NSCLC)患者中的联合分析——SAKK试验16/96、16/00、16/01、16/08和16/14

2025-11-100
OAAI
\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study

阿来替尼对比克唑替尼用于初治ALK阳性晚期非小细胞肺癌:III期ALEX研究最终总生存期分析

2025-10-170
OAAI
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2025-09-300
OAAI
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

晚期非小细胞肺癌患者接受双重CTLA-4和PD-L1或PD-1阻断治疗及生物标志物基础亚组分析的长期总生存:一项系统评价和重建个体患者数据荟萃分析

2025-09-290
PRE